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Abstract
Objective. To examine the relationship between the pre-
scribed target dose and the dose to healthy neurovascular
structures in patients with vestibular schwannomas treated
with stereotactic radiosurgery (SRS).
Study Design. Case series with chart review.
Setting. SRS center from 2011 to 2013.
Subjects. Twenty patients with vestibular schwannomas
treated at the center from 2011 to 2013.
Methods. Twenty patients with vestibular schwannomas were
included. The average radiation dose delivered to healthy
neurovascular structures (eg, carotid artery, basilar artery,
facial nerve, trigeminal nerve, and cochlea) was analyzed.
Results. Twenty patients with vestibular schwannomas who were
treated with fused computed tomography/magnetic resonance
imaging–guided SRS were included in the study. The prescribed
dose ranged from 10.58 to 17.40 Gy over 1 to 3 hypofractions
to cover 95% of the target tumor volume. The mean dose to the
carotid artery was 5.66 Gy (95% confidence interval [CI], 4.53-
6.80 Gy), anterior inferior cerebellar artery was 8.70 Gy (95% CI,
4.54-12.86 Gy), intratemporal facial nerve was 3.76 Gy (95% CI,
3.04-4.08 Gy), trigeminal nerve was 5.21 Gy (95% CI, 3.31-7.11
Gy), and the cochlea was 8.70 Gy (95% CI, 7.81-9.59 Gy).
Conclusions. SRS for certain vestibular schwannomas can
expose the anterior inferior cerebellar artery (AICA) and
carotid artery to radiation doses that can potentially initiate
atherosclerotic processes. The higher doses to the AICA and
carotid artery correlated with increasing tumor volume. The
dose delivered to other structures such as the cochlea and
intratemporal facial nerve appears to be lower and much less
likely to cause immediate complications when shielded.
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R
adiosurgery has been increasingly used over the past
decade in the management of vestibular schwanno-
mas and other skull base tumors. While improve-
ments in stereotactic radiosurgery (SRS) have allowed for
more precise dosing to tumors, the extent of exposure of
some surrounding healthy structures as a result of radiation
of vestibular schwannomas has not been well described.
Histological examination of experimental animal models
after high-dose radiation has demonstrated pathological
changes to the middle ear, inner ear, and skull base struc-
tures.1-3 Patients receiving radiation therapy for skull base
tumors have been also shown to develop accelerated athero-
sclerosis and cranial nerve palsies such as facial paresthesias
and weakness, as well as hearing loss, tinnitus, and imbal-
ance, partly due to radiation exposure of healthy neurovas-
cular structures of the skull base.4 Although better than
microsurgery, the long-term quality of life in patients with
vestibular schwannoma treated with SRS has been shown to
be reduced due to ongoing headaches, dizziness, hearing
loss, facial nerve weakness, and tinnitus.5 Thus, understand-
ing the radiation dose to the surrounding structures during
SRS can improve pretreatment patient counseling.
A few studies have measured the GammaKnife (GK)
radiation dosage to certain skull base, inner ear, middle ear,
and external ear structures.6-10 However, to our knowledge,
no studies to date have evaluated the amount of radiation
that healthy neural and vascular structures receive after
SRS. We aimed to evaluate the radiation doses delivered to
healthy neural and vascular structures of the skull base and
inner ear in patients treated for vestibular schwannomas.
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Methods
After institutional review board approval was obtained at
the University of California–Irvine, a retrospective analysis
of 20 consecutive patients with cerebellopontine angle
tumors was performed. These patients were all managed by
the senior author with assistance from the radiation oncol-
ogy and physician team via primary SRS between 2011 and
2013. All treatment plans were evaluated in the planning
software, using a dose sampling protocol, for each of the
structures listed in Table 1. Treatment planning was per-
formed with the Accuray Cyberknife Multiple Treatment
Planning System (Sunnyvale, CA). The normal structures
evaluated were identified by 2 authors independently and
confirmed by the senior author on computed tomography
(CT), magnetic resonance imaging (MRI), or fusion images.
The radiation to the vessels was measured at the wall in
various portions of the carotid artery in the petrous portion,
as demonstrated in Table 1. The horizontal carotid was
divided into 3 segments: proximal, mid, and distal. The
proximal, mid, and distal sections of the horizontal carotid
artery were defined as the wall of the proximal-most portion
of the artery near the cochlea, the midpoint on the same
axial cut toward the nasopharynx, and the distal-most por-
tion on the same cut near the nasopharynx, respectively.
The vertical segment was defined at the point right before
the transition of the vertical to horizontal carotid. Radiation
dosage to the anterior inferior cerebellar artery (AICA) was
also measured as the closest portion of the vessel near the
facial nerve in the cerebellopontine angle at the mid–
internal auditory canal (IAC) level on axial cuts. We were
unable to identify AICA in all patients. The basilar artery
was found and measured at the level of the IAC as well.
All neural structures were measured at their midpoint,
with the cursor on the midportion of the structure. The dose
to the trigeminal nerve was measured after its exit from the
pons on axial cuts, as well as after the prepontine cistern in
the distal temporal portion. The abducens nerve was mea-
sured medial to the facial nerve. The facial nerve was mea-
sured at several points, beginning with the proximal
cisternal portion (when not adherent to the tumor) and in
the labyrinthine segment. In addition, the radiation to the
facial nerve was also measured at the cisternal portion,
when possible, at the geniculate ganglion, the tympanic seg-
ment at the oval window, and the mastoid segment at the
level of the basal turn of the cochlea. We were unable to
consistently measure the cisternal portion of the facial nerve
due to the tumor proximity to the nerve in certain cases.
The glossopharyngeal nerve was measured on axial cuts just
lateral to the eighth nerve complex. Similarly, the cochlear
radiation was measured on the walls of the basal turn at the
round window, the distal basal turn, the middle turn, and the
apex.
The distance between the tumor’s lateral end and the
fundus of the IAC was measured (cerebrospinal fluid [CSF]
cap). This distance was correlated with the radiation dose to
the labyrinthine segment of the facial nerve, the mean dose
to the facial nerve, and the cochlear dose using a linear
regression. Tumor volume was correlated with the average
dose to the carotid artery and AICA using an adjusted R2
linear regression. A P value of\.05 was considered statisti-
cally significant.
Results
Twenty patients with vestibular schwannomas who were man-
aged at our SRS center from 2011 to 2013 were included in
this study. There were 8 female and 12 male patients. Thirteen
of the 20 patients had right-sided tumors. The minimum dose
delivered to 95% of tumor volume was 15.49 Gy, delivered
over 3 hypofractions in most patients, with only 1 patient
receiving unfractionated therapy. Generally, the dose per frac-
tion was set at a mean of 6.35 Gy, with an average treatment
duration of 36.4 minutes. The average total tumor size was
16.2 mm (length, including the IAC) 3 11.8 mm (parallel to
the petrous face) 3 10.5 mm (craniocaudal). The tumor sizes
range length was (6.4 – 27.6 mm) 3 (4.6 – 26.3 mm) 3 (4.6 –
22.1 mm). The average tumor volume was 1227 mm3 (range,
203-6335 mm3).
As seen in Table 2, all portions of the carotid artery
evaluated received a mean radiation dose of less than 6.77
Gy, with the overall average radiation dose delivered of
5.66 Gy. However, there was an extensive range seen
among the patients, ranging from 0.36 to 13.0 Gy with a
95% confidence interval (CI) of 4.53 to 6.80 Gy. Such a
Table 1. Neurovascular Structures Evaluated.
No. Structure
1 Carotid artery proximal portion
2 Carotid artery midportion
3 Carotid artery distal portion
4 Carotid artery vertical portion
5 Basilar artery
6 Anterior inferior cerebellar artery
7 Fifth nerve cisternal
8 Fifth nerve temporal
9 Sixth nerve
10 Facial nerve: labyrinthine segment
11 Facial nerve: geniculate
12 Facial nerve: middle ear
13 Facial nerve: mastoid portion
14 Facial nerve: cisternal
15 Facial nerve mean: total
16 Eighth nerve cisternal
17 Ninth nerve cisternal
18 Cochlear aqueduct: midportion
19 Cochlear aqueduct
20 Cochlea: basal turn
21 Cochlea: basal turn opposite end
22 Cochlea: middle turn
23 Cochlea: apex
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variation was seen in nearly all the structures evaluated, as
seen in Tables 3 and 4. Tumor volume demonstrated a sta-
tistically significant positive correlation with the radiation
dose to both the carotid artery (adjusted R2 = 0.556, P \
.001) and the AICA (adjusted R2 = 0.461, P = .038). This
correlation is demonstrated in Figure 1. The mean doses to
the cochlea (adjusted R2 = 0.042, P = .563) and the facial
nerve (adjusted R2 = 0.058, P = .729) demonstrated no cor-
relation. Overall, the middle turn of the cochlea received the
highest radiation dose (mean [SD], 9.37 [2.99] Gy), com-
pared with the basal turn at the round window (mean [SD],
7.55 [3.63] Gy), distal (at the second turn junction) basal
turn (mean [SD], 8.15 [2.96] Gy), or apex (mean [SD], 8.17
[2.45] Gy). There was no correlation between the distance
from the tumor’s lateral margin and the fundus of the IAC
(CSF cap) and the radiation dose to any of the different por-
tions of the cochlea. There was no correlation between the
distance from the tumor’s lateral margin and the fundus of
the IAC (CSF cap) and the radiation dose to any of the dif-
ferent portions of the cochlea.
Discussion
With the advent of SRS in the management of vestibular
schwannomas, there is an increasing population of patients
managed as such. As of 2011, 42% of neurotologists are
using SRS to treat vestibular schwannomas.11 This number
is continuing to trend upward, and surgical volume has been
decreasing, with 6 additional neurotologists per year opting
for SRS in the management of vestibular schwannomas.12,13
In addition, with the various complications of surgical resec-
tion, including those not seen in SRS14 and the outpatient
nature of radiosurgery, many patients are choosing radiosur-
gery. SRS has proven to be a safe,15-17 reliable alternative
with equivalent or superior results in select patients, despite
rare complications.16,17 New SRS technology delivers pre-
cise, calculated dosage with the guidance of fused CT and
MRI, which can be hypofractionated. However, SRS, like
any radiation modality, has its risks due to radiation dosage
to adjacent healthy neurovascular structures. Given the
Accuray software’s ability to create a more conformal plan
vs the isocenter-based plans of GK, we aimed to measure
the radiation dose to healthy neurovascular structures with
SRS treatment of vestibular schwannomas.
Radiation to arterial walls is known to be a factor in accel-
erated atherosclerosis.18,19 Other effects to the arterial system
also include luminal occlusion, thrombosis, and premature
vessel aging,20 with small- and medium-size vessels experien-
cing the greatest radiation damage. Less frequently, complica-
tions, such as undiscovered aneurysms, have also been
reported in the literature.21-23 Larger arteries, such as the caro-
tid artery, may also undergo stenosis in patients who have
been radiated.24-26 Typically, dosages even as low as 2 to 8
Gy have been shown to increase the risk of vascular
events.19,27,28 Doses greater than 8 Gy were reached in the car-
otid artery wall in 7 of our 20 (35%) patients. In addition, we
note that the mean radiation dose delivered to the carotid
artery correlated to the volume of the tumor, as shown in
Figure 1. We noted that the average tumor volume was over
4 times as large (2247 mm3) compared with the other patients
who received doses under 8 Gy (514 mm3). In our cohort, a
patient with a tumor less than or equal to 15.1 mm in size
received less than 8 Gy to the carotid artery wall, whereas a
patient with a tumor greater than or equal to 17.8 mm had
Table 2. Radiation to Vascular Structures.
Structure Mean (SD), Gy
95% Confidence
Interval
Carotid artery 5.67 4.53-6.80
Proximal portion 6.79 (3.05)
Midportion 5.86 (3.18)
Distal 4.01 (2.90)
Vertical 6.17 (3.73)
Basilar artery 2.05 (1.59) 1.33-2.78
Anterior inferior
cerebellar artery
8.70 (5.74) 4.54-12.86
Table 3. Radiation to Cranial Nerves.
Structure Mean (SD), Gy
Trigeminal nerve
Cisternal 7.73 (5.65)
Temporal 2.69 (2.18)
Abducens nerve 2.97 (2.44)
Facial nerve
Labyrinthine segment 10.46 (4.83)
Geniculate 3.76 (2.38)
Middle ear 5.42 (3.55)
Mastoid portion 4.49 (4.87)
Cisternal 12.07 (6.42)
Mean total 3.76 (2.95)
Eighth nerve cisternal 11.74 (6.07)
Ninth nerve cisternal 8.22 (6.66)
Table 4. Radiation to Various Portions of the Cochlea.
Structure Mean (SD), Gy
Cochlear aqueduct: midportion 10.13 (5.49)
Cochlear aqueduct 10.66 (3.07)
Cochlea
Basal turn 7.55 (3.63)
Basal turn at second turn junction 8.15 (2.96)
Middle turn 9.37 (2.99)
Apex 8.17 (2.45)
Mean dose to cochlea 8.31
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radiation doses greater than 8 Gy to the carotid artery wall.
Since many of the radiation-induced effects can occur up to 10
years after the inciting event,29 patients with moderate- or
large-size tumors undergoing SRS should be informed about a
possible atherosclerosis risk in the future.
Similarly, the AICA was exposed to up to 16 Gy of
radiation, and the mean dosage was above the 8 Gy thresh-
old (8.70 Gy). The dose to the AICA also correlated to the
tumor volume. The basilar artery exhibited low doses of
radiation with a mean dose of 2.05 Gy (95% confidence
interval [CI], 1.33-2.78 Gy), exhibiting a low risk of radia-
tion. Given the toxic doses to the carotid artery and AICA,
patients, especially younger patients with larger tumors,
should be counseled on the risk of atherosclerosis even with
short radiation exposure. In addition, we should routinely
shield the carotid during the planning to potentially ensure
that less than 8 Gy of radiation is given to the carotid. The
AICA should ideally be shielded as well.
Cranial nerves also have been previously evaluated in radia-
tion studies and have been shown to have a dose-related
effect.30 The trigeminal nerve has preservation rates of greater
than 90%.30,31 Doses below 12.50 Gy are typically considered
safe with an extremely low (0.7%) rate of facial paresthesia or
anesthesia; however, they noted that the risk of cranial neuro-
pathy increased by 6-fold for each 2.50-Gy increase over
12.50 Gy.32 We note that the mean radiation dose to the cister-
nal portion of the trigeminal nerve was 8.30 Gy and 2.89 Gy
for the temporal portion of the trigeminal nerve. In 1 patient
with a 27-mm tumor (6355-mm3 volume), the largest in our
series, the radiation dose to the trigeminal nerve exceeded the
above threshold, with the highest at 17.09 Gy. Fortunately,
that patient did not develop facial paresthesia. In small- to
medium-sized tumors, radiation doses to the trigeminal nerve
are unlikely to reach toxic levels when treating vestibular
schwannomas with SRS.
We were unsuccessful in demonstrating a relationship
between the lateral extension of the tumor in the internal audi-
tory canal and the radiation dosages delivered to the facial
nerve and the cochlea. This, however, may be an artifact of
our small sample size and our active shielding of the cochlea
and the intratemporal facial nerve in our planning. Further-
more, considering that the long-term effects of radiation may
take 10 or more years to appear, radiosurgery should be con-
sidered with caution in patients who are younger and have
larger tumors. Potentially, a subtotal resection with radiation
for regrowth should be considered in those patients who may
be more concerned about facial nerve and vascular outcomes.
Increasingly, neurotologists are opting for SRS in the man-
agement of vestibular schwannomas.11-13 A recent retrospective
review of the Surveillance, Epidemiology, and End Results
(SEER) database demonstrated an overall shift toward more
conservative management of vestibular schwannomas with a
decreasing number of patients receiving primary microsurgery.33
While this article demonstrated a potential toxicity of the AICA
and carotid artery with the treatment of tumors, particularly
larger ones, SRS has previously been demonstrated as an effec-
tive alternative with lower complication rates in select
patients.13,14,34-36 This treatment modality allows for 96% to
99% reported tumor control rates.37 Tumor control rates are
generally better for smaller tumors (Koos grade 1) compared
with Koos grade 2 or higher tumors with a hearing preservation
rate of 85% and 75%, respectively.37,38 Despite the possible
arterial toxicity presented in our study when treating larger
tumors, SRS can allow for good tumor control with high hear-
ing preservation rates and should be strongly considered a treat-
ment option for select patients with vestibular schwannomas.
This study is limited by the small sample size. Another
limitation, inherent to all studies of this nature, is that this
study analyzes patients treated by a single individual at a
single institution. A multi-institutional study of this nature
is possible but may introduce some bias when selecting the
location for each measurement. We chose those years to
ensure adequate follow-up of the patients regarding their
facial nerve, trigeminal nerve, and imbalance. Hearing
results, we felt, were beyond the scope of this study and
will be reported in the future with a larger data set and
more long-term follow-up. In addition, data on atherosclero-
sis development in our patient cohort are lacking. Given the
long-term and multifactorial etiology of atherosclerosis, we
believe that this issue warrants further study with prospec-
tive data gathering with magnetic resonance arteriography.
Conclusions
The evidence from this radiation dosimetry evaluation shows
that SRS generally allows for safe radiation dosages to sur-
rounding structures. Patients with tumors that were 17.8 mm or
larger received radiation doses of greater than 8 Gy to the caro-
tid artery wall, which can lead to atherosclerosis. Patient with
larger tumors received doses of radiation to the AICA that can
also lead to atherosclerosis. The dose delivered to other struc-
tures, such as the cochlea and facial nerve, appears to be lower
and much less likely to cause immediate complications.
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